Wael Sakr

Wael Sakr

wsakr@med.wayne.edu

(313) 745-2525

Wael Sakr

Office Address

Department of Pathology
3990 John R. Road
Harper University Hospital, Detroit Medical Center
Detroit, MI 48202

Administrative Contact

Lydia Cuper
Phone: (313) 745-2520
or
Brenda Batts
Phone: (313) 577-1102

Position Title

Professor
Chairman, Pathology Department
Specialist-in-chief of Pathology, DMC

Education Training

M.D. (1980): University of Damascus, Damascus, Syria

Fellowship
1985-1987: Harper Hospital, Wayne State University School of Medicine, Detroit, MI, USA, in Surgical Pathology

Areas of Interest

Prostate Cancer, Surgical pathology, urologic pathology, head and neck pathology

Research

Dr. Sakr has been interested in the histopathological and biological traits of preneoplastic changes of the prostate. His work contributed to a current consensus that high grade prostatic intraepithelial neoplasm is a precursor of prostate adenocarcinoma. Dr. Sakr has been actively involved in numerous clinical trials as an expert pathologist. In other clinical studies, Dr. Sakr is interested in evaluating genetic changes and expression profiling as markers for cancer diagnosis and prognosis. In addition, Dr. Sakr is an active investigator on several funded basic research projects on the underlying molecular mechanism of prostate tumor progression and metastasis.

 

Research Interests

Urological malignancies, preneoplastic diseases, prostate, molecular markers, and cancer biology

Residency

1982-1985: Booth Memorial Hospital, New York University, New York, NY, USA

Publications

1. Sakr WA, 1998, High‑grade prostatic intraepithelial neoplasia: additional links to a potentially more aggressive prostate cancer? [editorial; comment] J Natl Cancer Inst; 90:486‑487. 
2. Yin, S, Li, X, Meng, Y. Finley, RL Jr, Sakr, W, Yang, H, Reddy, N, and Sheng, S, 2005, Tumor suppressive maspin regulates cell response to oxidative stress by direct Interaction with glutathione s-transferase, J. Biol. Chem. 280: 4985-96.
3. Marshall, JR, Sakr, WA, Wood, D, Berry, D, Tangen, C, Parker, F, Thompson, I, Lippman, SM, Lieberman, R, Alberts, D,  Jarrard, D, Coltman, C, Greenwald, P, Minasian, L,  and Crawford, ED, 2006, Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia, Cancer Epidemiology Biomarkers & Prevention, 15: 1479-84.
4. Li, X, Yin, S, Sakr, W, Meng, Y, Zhao, Z, and Sheng, S, 2006, Endogenous inhibition of histone deacetylase 1 by tumor suppressive maspin, Cancer Res, 66: 9330-7.
5. Rahman KM, Banerjee S, Ali S, Ahmad A, Wang Z, Kong D and Sakr W, 2009, DIM enhances Taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation, Cancer Res, 69: 4468-75.
 

← Return to listing